vs

Side-by-side financial comparison of Axos Financial, Inc. (AX) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Axos Financial, Inc. is the larger business by last-quarter revenue ($392.2M vs $225.6M, roughly 1.7× Organogenesis Holdings Inc.). Axos Financial, Inc. runs the higher net margin — 31.8% vs 19.4%, a 12.4% gap on every dollar of revenue. Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 16.1%).

Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

AX vs ORGO — Head-to-Head

Bigger by revenue
AX
AX
1.7× larger
AX
$392.2M
$225.6M
ORGO
Higher net margin
AX
AX
12.4% more per $
AX
31.8%
19.4%
ORGO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
16.1%
AX

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
AX
AX
ORGO
ORGO
Revenue
$392.2M
$225.6M
Net Profit
$124.7M
$43.7M
Gross Margin
Operating Margin
28.1%
Net Margin
31.8%
19.4%
Revenue YoY
78.1%
Net Profit YoY
18.5%
469.5%
EPS (diluted)
$2.15
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AX
AX
ORGO
ORGO
Q1 26
$392.2M
Q4 25
$385.1M
$225.6M
Q3 25
$323.4M
$150.9M
Q2 25
$321.4M
$101.0M
Q1 25
$308.8M
$86.7M
Q4 24
$307.9M
$126.7M
Q3 24
$320.7M
$115.2M
Q2 24
$290.9M
$130.2M
Net Profit
AX
AX
ORGO
ORGO
Q1 26
$124.7M
Q4 25
$128.4M
$43.7M
Q3 25
$112.4M
$21.6M
Q2 25
$110.7M
$-9.4M
Q1 25
$105.2M
$-18.8M
Q4 24
$104.7M
$7.7M
Q3 24
$112.3M
$12.3M
Q2 24
$104.9M
$-17.0M
Gross Margin
AX
AX
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
AX
AX
ORGO
ORGO
Q1 26
Q4 25
45.6%
28.1%
Q3 25
46.3%
13.7%
Q2 25
48.5%
-12.5%
Q1 25
47.9%
-30.9%
Q4 24
48.8%
8.1%
Q3 24
49.6%
5.4%
Q2 24
49.6%
-10.7%
Net Margin
AX
AX
ORGO
ORGO
Q1 26
31.8%
Q4 25
33.3%
19.4%
Q3 25
34.7%
14.3%
Q2 25
34.4%
-9.3%
Q1 25
34.1%
-21.7%
Q4 24
34.0%
6.1%
Q3 24
35.0%
10.7%
Q2 24
36.0%
-13.1%
EPS (diluted)
AX
AX
ORGO
ORGO
Q1 26
$2.15
Q4 25
$2.22
$0.31
Q3 25
$1.94
$0.11
Q2 25
$1.89
$-0.10
Q1 25
$1.81
$-0.17
Q4 24
$1.80
$0.05
Q3 24
$1.93
$0.09
Q2 24
$1.75
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AX
AX
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.1B
$300.1M
Total Assets
$29.2B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AX
AX
ORGO
ORGO
Q1 26
Q4 25
$1.0B
$93.7M
Q3 25
$2.6B
$63.7M
Q2 25
$1.9B
$73.1M
Q1 25
$2.0B
$110.0M
Q4 24
$2.4B
$135.6M
Q3 24
$2.6B
$94.3M
Q2 24
$2.0B
$89.9M
Total Debt
AX
AX
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
$312.7M
Q1 25
$377.4M
Q4 24
$358.7M
Q3 24
$313.5M
$62.3M
Q2 24
$325.7M
$63.8M
Stockholders' Equity
AX
AX
ORGO
ORGO
Q1 26
$3.1B
Q4 25
$2.9B
$300.1M
Q3 25
$2.8B
$255.1M
Q2 25
$2.7B
$233.2M
Q1 25
$2.6B
$242.9M
Q4 24
$2.5B
$262.9M
Q3 24
$2.4B
$278.5M
Q2 24
$2.3B
$263.5M
Total Assets
AX
AX
ORGO
ORGO
Q1 26
$29.2B
Q4 25
$28.2B
$598.7M
Q3 25
$27.4B
$509.8M
Q2 25
$24.8B
$461.1M
Q1 25
$24.0B
$467.4M
Q4 24
$23.7B
$497.9M
Q3 24
$23.6B
$446.3M
Q2 24
$22.9B
$443.2M
Debt / Equity
AX
AX
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
0.12×
Q1 25
0.14×
Q4 24
0.14×
Q3 24
0.13×
0.22×
Q2 24
0.14×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AX
AX
ORGO
ORGO
Operating Cash FlowLast quarter
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AX
AX
ORGO
ORGO
Q1 26
Q4 25
$104.1M
$39.4M
Q3 25
$118.4M
$3.1M
Q2 25
$490.3M
$-32.9M
Q1 25
$73.7M
$-19.9M
Q4 24
$162.5M
$10.9M
Q3 24
$70.8M
$8.7M
Q2 24
$305.5M
$4.7M
Free Cash Flow
AX
AX
ORGO
ORGO
Q1 26
Q4 25
$85.4M
$34.8M
Q3 25
$109.3M
$844.0K
Q2 25
$436.1M
$-36.5M
Q1 25
$65.1M
$-23.6M
Q4 24
$156.4M
$7.6M
Q3 24
$53.0M
$6.1M
Q2 24
$269.5M
$2.9M
FCF Margin
AX
AX
ORGO
ORGO
Q1 26
Q4 25
22.2%
15.4%
Q3 25
33.8%
0.6%
Q2 25
135.7%
-36.1%
Q1 25
21.1%
-27.2%
Q4 24
50.8%
6.0%
Q3 24
16.5%
5.3%
Q2 24
92.6%
2.2%
Capex Intensity
AX
AX
ORGO
ORGO
Q1 26
Q4 25
4.9%
2.1%
Q3 25
2.8%
1.5%
Q2 25
16.9%
3.6%
Q1 25
2.8%
4.2%
Q4 24
2.0%
2.7%
Q3 24
5.5%
2.2%
Q2 24
12.4%
1.4%
Cash Conversion
AX
AX
ORGO
ORGO
Q1 26
Q4 25
0.81×
0.90×
Q3 25
1.05×
0.14×
Q2 25
4.43×
Q1 25
0.70×
Q4 24
1.55×
1.43×
Q3 24
0.63×
0.71×
Q2 24
2.91×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AX
AX

Net Interest Income$306.3M78%
Noninterest Income$86.0M22%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons